Nanocapsules as carriers for the transport and targeted delivery of bioactive molecules

Nanocomposite Particles for Bio-Applications: Materials and Bio-Interfaces

Volumn , Issue , 2011, Pages 45-67

  Hervella, P ^a   Lollo, G ^a   Oyarzun Ampuero, F ^a   Rivera, G ^a   Torres, D ^a   Alonso, M J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880184806     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814267816     Document Type: Chapter

References (90)

1. Couvreur, P., Tulkens, P. and Roland, M. (1977). Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett., 84, pp. 323-326.
2. Legrand, P., Barratt, G., Mosqueira, V., Fessi, H. and Devissaguet, J.P. (1999). Polymeric nanocapsules as drug delivery systems: A review, STP Pharm. Sci., 9, pp. 411-418.
3. Couvreur, P., Barratt, G., Fattal, E., Legrand, P. and Vauthier, C. (2002). Nanocapsule technology: A review, Crit Rev Ther Drug Carrier Syst., 19, pp. 99-134.
4. Couvreur, P., Kante, B. and Roland, M. (1979). Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties, J Pharm Pharmacol., 31, pp. 331-332.
5. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N. and Benita, S. (1989). Nanocapsule formation by interfacial polymer deposition following solvent deplacement, Int J Pharm., 55, pp. 25-28.
6. Heurtault, B., Saulnier, P., Pech, B., Proust, J. E. and Benoit, J. P. (2002). A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharm Res., 19, pp. 875-880.
7. Prego, C., Torres, D. and Alonso, M. J. (2006). Chitosan nanocapsules: A new carrier for nasal peptide delivery, JDDST, 16, pp. 331-337.
8. Prego, C., Torres, D. and Alonso, M. J. (2006). Chitosan nanocapsules as carriers for oral peptide delivery: Effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo effectiveness, J Nanosci Nanotechnol, 6, pp. 2921-2928.
9. Lozano, M. V., Torrecilla, D., Torres, D., Vidal, A., Dominguez, F. and Alonso, M. J. (2008). Highly efficient system to deliver taxanes into tumor cells: Docetaxel-loaded chitosan oligomer colloidal carriers, Biomacromolecules, 9, pp. 2186-2193.
10. Desai, M. P., Labhasetwar, V., Amidon, G. L. and Levy, R. J. (1996). Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size, Pharm Res., 13, pp. 1838-1845.
11. Vila, A., Gill, H., McCallion, O. and Alonso, M. J. (2004). Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density, J Control Release, 98, pp. 231-244.
12. Yin Win, K. and Feng, S. (2005). Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26, pp. 2713-2722.
13. Quintanar-Guerrero, D., Allemann, E., Doelker, E. and Fessi, H. (1998).Preparation and characterization of nanocapsnles from preformed polymers by a new process based on emulsification-diffusion technique, Pharm. Res., 15, pp. 1056-1062.
14. Moinard-Checot, D., Chevalier, Y., Briancon, S., Beney, L. and Fessi, H. (2008). Mechanism of nanocapsules formation by the emulsion-diffusion process, J. Colloid Interface Sci., 317, pp. 458-468.
15. Rube, A., Hause, G., Mader, K. and Kohlbrecher, J. (2005). Core-shell structure of Miglyol/poly(D,L-lactide)/Poloxamer nanocapsules studied by small-angle neutron scattering, J Control Release, 107, pp. 244-252.
16. Calvo, P., Vila-Jato, J. L. and Alonso, M. J. (1997). Evaluation of cationic polymercoated nanocapsules as ocular drug carriers, Int. J. Pharm., 153, pp. 41-50.
17. Guinebretiere, S., Briancon, S., Lieto, J., Mayer, C. and Fessi, H. (2002). Study of the emulsion-diffusion of solvent: Preparation and characterization of nanocapsules, Drug Dev. Res., 57, pp. 18-33.
18. Wohlgemuth, M. and Mayer, C. (2003). Pulsed field gradient NMR on polybutylcyanoacrylate nanocapsules. J Colloid Interface Sci.260, pp. 324-331.
19. Hillaireau, H., Le Doan, T., Chacun, H., Janin, J. and Couvreur, P. (2007). Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers, Int. J. Pharm., 331, pp. 148-152.
20. Vauthier, C. and Bouchemal, K. (2008). Methods for the Preparation and Manufacture of Polymeric Nanoparticles, Pharm. Res., 1-34.
21. Gallardo, M., Couarraze, G., Denizot, B., Treupel, L., Couvreur, P. and Puisieux, F. (1993). Study of the mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate, Int. J. Pharm., 100, pp. 55-64.
22. Puglisi, G., Fresta, H. T. M., Giammona, G. and Ventura, C. A. (1995). Influence of the preparation conditions on poly(ethylcyanoacrylate) nanocapsule formation. Int. J. Pharm., 125, pp. 283-287.
23. Fresta, M., Cavallaro, G., Giammona, G., Wehrli, E. and Puglisi, G. (1996). Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials., 17, pp. 751-758.
24. Aboubakar, M., Puisieux, F., Couvreur, P., Deyme, M. and Vauthier, C. (1999). Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization., J. Biomed. Mater. Res., 47, pp. 568-576.
25. Lowe, P. J. and Temple, C. S. (1994). Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: Protection against proteases and effect on intestinal absorption in rats, J. Pharm. Pharmacol., 46, pp. 547-552.
26. Vauthier, C., Labarre, D. and Ponchel, G. (2007). Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J. Drug Target., 15, pp. 641-663.
27. Watnasirichaikul, S., Davies, N. M., Rades, T. and Tucker, I. G. (2000). Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions, Pharm. Res., 17, pp. 684-689.
28. Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A. and Couvreur, P. (2000). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides, Pharm Res., 17, pp. 707-714.
29. Vranckx, H., Demoustier, M. and Deleers, M. (1996). A new nanocapsule formulation with hydrophilic core: Application to the oral administration of salmon calcitonin in rats. Eur. J. Pharm. Biopharm., 42, pp. 345-347.
30. Al Khouri Fallouh, N., Roblot-Treupel, L. and Fessi, H. (1986). Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int. J. Pharm., 28, pp. 125-132.
31. Nassar, T., Rom, A., Nyska, A. and Benita, S. (2008). A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs, Pharm. Res., 25, pp. 2019-2029.
32. Guinebretiere, S., Briançon, S., Fessi, H., Teodorescu, V.S. and Blanchin, M.G. (2002).Nanocapsules of biodegradable polymers: Preparation and characterization by direct high resolution electron microscopy. Mater Sci Eng C.21, pp. 137-142.
33. Cauchetier, E., Deniau, M., Fessi, H., Astier, A. and Paul, M. (2003). Atovaquoneloaded nanocapsules: Influence of the nature of the polymer on their in vitro characteristics, Int. J. Pharm., 250, pp. 273-281.
34. De Campos, A. M., Sanchez, A., Gref, R., Calvo, P. and Alonso, M. J. (2003).The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa, Eur. J. Pharm. Sci., 20, pp. 73-81.
35. Mosqueira, V. C. F., Legrand, P., Gulik, A., Bourdon, O., Gref, R., Labarre, D. and Barratt, G. (2001). Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules, Biomaterials, 22, pp. 2967-2979.
36. Mosqueira, V. C. F., Legrand, P., Morgat, J. L., Vert, M., Mysiakine, E., Gref, R., Devissaguet, J. P. and Barratt, G. (2001). Biodistribution of long-circulating PEGgrafted nanocapsules in mice: Effects of PEG chain length and density, Pharm. Res., 18, pp. 1411-1419.
37. Bouclier, C., Moine, L., Hillaireau, H., Marsaud, V.R., Connault, E., Opolon, P., Couvreur, P., Fattal, E. and Renoir, J.-M. (2008). Physicochemical Characteristics and Preliminary in Vivo Biological Evaluation of Nanocapsules Loaded with siRNA Targeting Estrogen Receptor Alpha, Biomacromolecules, 9, pp. 2881-2890.
38. Prego, C., Torres, D., Fernandez-Megia, E., Novoa-Carballal, R., Quinoa, E. and Alonso, M. J. (2006). Chitosan-PEG nanocapsules as new carriers for oral peptide delivery: Effect of chitosan pegylation degree, J. Control. Release., 111, pp. 299-308.
39. Preetz, C., Rube, A., Reiche, I., Hause, G. and Mader, K. (2008). Preparation and characterization of biocompatible oil-loaded polyelectrolyte nanocapsules. Nanomedicine, 4, pp. 106-114.
40. Heurtault, B., Saulnier, P., Pech, B., Benoit, J. P. and Proust, J. E. (2003). Interfacial stability of lipid nanocapsules, Colloids Surf B Biointerfaces, 30, pp. 225-235.
41. Heurtault, B., Saulnier, P., Pech, B., Proust, J. E. and Benoit, J. P. (2003). Physicochemical stability of colloidal lipid particles, Biomaterials, 24, pp. 4283-4300.
42. Heurtault, B., Saulnier, P., Pech, B., Venier-Julienne, M. C., Proust, J. E., Phan-Tan- Luu, R. and Benoit, J. P. (2003). The influence of lipid nanocapsule composition on their size distribution, Eur. J. Pharm. Sci., 18, pp. 55-61.
43. Anton, N., Gayet, P., Benoit, J. P. and Saulnier, P. (2007). Nano-emulsions and nanocapsules by the PIT method: An investigation on the role of the temperature cycling on the emulsion phase inversion, Int. J. Pharm., 344, pp. 44-52.
44. Dhanikula, B. A., Khalid, M. N., Lee, S. D., Yeung, R., Risovic, V., Wasan, K. M. and Leroux, J. C. (2007). Long circulating lipid nanocapsules for drug detoxification, Biomaterials, 28, pp. 1248-1257.
45. Khalid, M. N., Simard, P., Hoarau, D., Dragomir, A. and Leroux, J. C. (2006). Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors, Pharm. Res., 23, pp. 752-758.
46. Prego, C., Garcia, M., Torres, D. and Alonso, M. J. (2005). Transmucosal macromolecular drug delivery, J. Control Release., 101, pp. 151-162.
47. Csaba, N., Garcia-Fuentes, M. and Alonso, M. J. (2006). The performance of nanocarriers for transmucosal drug delivery, Expert. Opin. Drug Deliv., 3, pp. 463-478.
48. Pinto Reis, C., Neufeld, R. J., Ribeiro, A. J. and Veiga, F. (2006). Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems, Nanomedicine, 2, pp. 53-65.
49. Alonso, M. J. (2004). Nanomedicines for overcoming biological barriers, Biomed. Pharmacother., 58, pp. 168-172.
50. des Rieux, A., Fievez, V., Garinot, M., Schneider, Y. J. and Preat, V. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach, J. Control. Release., 116, pp. 1-27.
51. Prego, C., Fabre, M., Torres, D. and Alonso, M. J. (2006). Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery, Pharm. Res., 23, pp. 549-556.
52. Damgé, C., Michel, C., Aprahamian, M. and Couvreur, P. (1988). New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier, Diabetes, 37, pp. 246-251.
53. Damgé, C., Vranckx, H., Balschmidt, P. and Couvreur, P. (1997). Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci., 86, pp. 1403-1409.
54. Pinto-Alphandary, H., Aboubakar, M., Jaillard, D., Couvreur, P. and Vauthier, C. (2003). Visualization of insulin-loaded nanocapsules: In vitro and in vivo studies after oral administration to rats, Pharm. Res., 20, pp. 1071-1084.
55. Cournarie, F., Auchere, D., Chevenne, D., Lacour, B., Seiller, M. and Vauthier, C. (2002). Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats, Int. J. Pharm., 242, pp. 325-328.
56. Ubrich, N., Schmidt, C., Bodmeier, R., Hoffman, M. and Maincent, P. (2005). Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles, Int. J. Pharm., 288, pp. 169-175.
57. Staniscuaski Guterres, S., Fessi, H., Barratt, G., Puisieux, F. and Devissaguet, J. P. (1995). Poly(D,L-Lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: Gastrointestinal tolerance following intravenous and oral administration, Pharm. Res., 12, pp. 1545-1547.
58. Limayem Blouza, I., Charcosset, C., Sfar, S. and Fessi, H. (2006). Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use, Int. J. Pharm., 325, pp. 124-131.
59. Nassar, T., Rom, A., Nyska, A. and Benita, S. (2009). Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug, J. Control Release, 133, pp. 77-84.
60. Peltier, S., Oger, J. M., Lagarce, F., Couet, W. and Benoit, J. P. (2006). Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules, Pharm. Res., 23, pp. 1243-1250.
61. Barar, J., Javadzadeh, A. R. and Omidi, Y. (2008). Ocular novel drug delivery: Impacts of membranes and barriers, Expert Opin. Drug Deliv., 5, pp. 567-581.
62. Lang, J. C. (1995). Ocular drug delivery conventional ocular formulations. Adv. Drug Deliv. Rev., 16, pp. 39-43.
63. Losa, C., Marchal-Heussler, L., Orallo, F., Vila-Jato, J. L. and Alonso, M. J. (1993). Design of new formulations for topical ocular administration: Polymeric nanocapsules containing metipranolol, Pharm. Res., 10, pp. 80-87.
64. Marchal-Heussler, L., Fessi, H., Devissaguet, J. P., Hoffman, M. and Maincent, P. (1992). Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: Polyisobutylcyanoacrylate, polylactic-co-glycolic acid, polyepsilon- caprolactone, STP Pharma Sciences, 2, pp. 98-104.
65. Marchal-Heussler, L., Sirbat, D., Hoffman, M. and Maincent, P. (1993). Poly(e- caprolactone) nanocapsules in carteolol ophthalmic delivery, Pharm. Res., 10, pp. 386-390.
66. Desai, S. D. and Blanchard, J. (2000). Pluronic ® F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine, Drug Delivery: J. Delivery and Targeting Therapeutic Agents, 7, pp. 201-207.
67. Calvo, P., Sanchez, A., Martinez, J., Lopez, M. I., Calonge, M., Pastor, J. C. and Alonso, M. J. (1996). Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A., Pharm Res., 13, pp. 311-315.
68. Le Bourlais, C. A., Chevanne, F., Turlin, B., Acar, L., Zia, H., Sado, P. A., Needham, T. E. and Leverge, R. (1997). Effect of cyclosporine A formulations on bovine corneal absorption: Ex-vivo study, J. Microencapsulation, 14, pp. 457-467.
69. Calvo, P., Thomas, C., Alonso, M. J., Vila-Jato, J. L. and Robinson, J. R. (1994). Study of the mechanism of interaction of poly(E-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy, Int. J. Pharm., 103, pp. 283-291.
70. Calvo, P., Vila-Jato, J. L. and Alonso, M. J. (1996). Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers, J. Pharm. Sci., 85, pp. 530-536.
71. Calvo, P., Alonso, M. J., Vila-Jato, J. L. and Robinson, J. R. (1996). Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers, J. Pharm. Pharmacol., 48, pp. 1147-1152.
72. Alonso, M. J. and Sanchez, A. (2003). The potential of chitosan in ocular drug delivery, J. Pharm. Pharmacol., 55, pp. 1451-1463.
73. Gottesman, M. M., Fojo, T. and Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters, Nat. Rev. Cancer, 2, pp. 48-58.
74. Ehdaie, B. (2008).Application of Nanotechnology in Cancer Research: Review of Progress in the National Cancer Institute's Alliance for nanotechnology.
75. McNeil, S. E. (2005). Nanotechnology for the biologist, J. Leukoc. Biol., 78, pp. 585-594.
76. Iyer, A. K., Khaled, G., Fang, J. and Maeda, H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discov. Today, 11, pp. 812-818.
77. Greish, K. (2007). Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines, J. Drug Target., 15, pp. 457-464.
78. Brigger, I., Dubernet, C. and Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis, Adv. Drug Deliv. Rev., 54, pp. 631-651.
79. Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P. and Benoit, J. P. (2006). A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats, Mol. Cancer Ther., 5, pp. 1710-1722.
80. Lenaerts, V., Labib, A., Chouinard, F., Rousseau, J., Ali, H. and Van Lier, J. (1995). Nanocapsules with a reduced liver uptake: Targeting of phthalocyanines to EMT-6 mouse mammary tumor in vivo, Eur. J. Pharm. Biopharm., 41, pp. 38-43.
81. Lacoeuille, F., Hindre, F., Moal, F., Roux, J., Passirani, C., Couturier, O., Cales, P., Le Jeune, J. J., Lamprecht, A. and Benoit, J. P. (2007). In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel, Int. J. Pharm., 344, pp. 143-149.
82. Fattal, E. and Bochot, A. (2008). State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers, Int. J. Pharm., 364, pp. 237-248.
83. Li, X. and Chan, W. K. (1999). Transport, metabolism and elimination mechanisms of anti-HIV agents, Adv. Drug. Deliv. Rev., 39, pp. 81-103.
84. Nakada, Y., Fattal, E., Foulquier, M. and Couvreur, P. (1996). Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice, Pharm. Res., 13, pp. 38-43.
85. Schwab, G., Chavany, C., Duroux, I., Goubin, G., Lebeau, J., Helene, C. and Saison- Behmoaras, T. (1994). Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice, Proc. Natl. Acad Sci. U S A.91, pp. 10460-10464.
86. Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A. and Couvreur, P. (2001). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides, Int. J. Pharm., 214, pp. 13-16.
87. Lambert, G., Bertrand, J. R., Fattal, E., Subra, F., Pinto-Alphandary, H., Malvy, C., Auclair, C. and Couvreur, P. (2000). EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice, Biochem. Biophys. Res. Commun., 279, pp. 401-406.
88. Toub, N., Bertrand, J. R., Malvy, C., Fattal, E. and Couvreur, P. (2006). Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model, Oligonucleotides, 16, pp. 158-168.
89. Toub, N., Bertrand, J. R., Tamaddon, A., Elhamess, H., Hillaireau, H., Maksimenko, A., Maccario, J., Malvy, C., Fattal, E. and Couvreur, P. (2006). Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma, Pharm. Res., 23, pp. 892-900.
90. Bouclier, C., Moine, L., Hillaireau, H., Marsaud, V., Connault, E., Opolon, P., Couvreur, P., Fattal, E. and Renoir, J. M. (2008). Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha, Biomacromolecules, 9, pp. 2881-2890.